Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$32.84
-$0.32(-1.18%)
At close: 4:00 PM EST
$32.84
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $40.06
Previous CloseN/A
Volume219.80K
Average Volume (3M)950.13K
Market Cap
$1.85B
Enterprise Value$414.73M
Total Cash (Recent Filing)$786.51M
Total Debt (Recent Filing)$7.68M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 12, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding57,597,940
10 Day Avg. Volume814,002
30 Day Avg. Volume950,131
Financial Highlights & Ratios
PEG Ratio3.15
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-12.11
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue232.82
Enterprise Value/Gross Profit-452.04
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$73.38Price Target Upside123.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial HealthStructure remains well-capitalized with $836.9M in cash, cash equivalents, and short-term investments, indicating strong financial health to support ongoing research and development.
Market AdvantageThe potential for aleniglipron to be the second approved, oral small molecule GLP-1Ra without a fasting requirement is viewed as a significant advantage.
Product DevelopmentThe completion of enrollment in the ACCESS I and ACCESS II Phase 2b studies for aleniglipron, an oral small molecule GLP-1R agonist, enhances Structure's competitive position in the obesity treatment field.
Bears Say
Clinical Trial ChallengesApproximately 25% of participants discontinued the study for any reason across all arms, indicating some challenges with participant retention.
Insurance And Cost BarriersInsurance coverage and cost of therapy is a primary barrier to treatment for patients.
Market ReactionRecent obesity data for a similar drug, orfoglipron, received poorly by investors, highlighting the risk of market reactions to clinical trial outcomes.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $40.06 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.85B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 12, 2025 which is in 4 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 06, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.065.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,597,940 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -0.674%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.38 (123.45% Upside)
$73.38 (123.45% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.72%
12-Months-Change
Fundamentals
Return on Equity
-21.19%
Trailing 12-Months
Asset Growth
-13.79%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$73.38
▲(123.45% Upside)
Technical Analysis
Ownership Overview
11.90% Insiders
25.93% Mutual Funds
46.09% Other Institutional Investors
14.90% Public Companies and Individual Investors